 |
| October
2, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Kate Torchilin, Ph.D., M.B.A., CEO and
President, Mirai Bio |
| In
this CEO Q&A, Torchilin discusses the
delivery bottleneck that inspired Mirai's
founding, what differentiates its
integrated LNP platform, the milestone
that took a partner program from concept
to IND-enabling studies in under ten
months, and leading within the Flagship
Pioneering ecosystem. More |
|
|
- Bambusa Therapeutics: Initiates Subcutaneous
Dosing of BBT001 in Atopic Dermatitis,
Following Compelling Intravenous
Proof-of-Concept Data More
- Clear Scientific: Positive Phase 2
Results for CS-1103, the First
Investigational Therapeutic That Removes
Fentanyl From the Body More
- Cullinan Therapeutics: New Drug Application
Submission Initiated for Zipalertinib Plus
Chemotherapy in First-Line EGFR Exon 20
Insertion Mutation NSCLC for Review Under FDA
Real-Time Oncology Review Program More
- Dana-Farber Cancer Institute: Novel
Treatment Combination Improves
Progression-Free Survival in Most Common Form
of Metastatic Breast Cancer
More
- Ernexa Therapeutics: CEO Corner Highlights
Appointment of Dr. Robert J. Spiegel as
Company Sharpens Oncology Focus and Advances
ERNA-101 Toward the Clinic
More
- Replimune: TUDRIQEV Now Available in the
U.S. for Advanced Melanoma
More
- Roswell Park, Generate Biomedicines: Launch
Exclusive Clinical Trial of ‘Armored’ CAR T
Therapy for Ovarian Cancer More
- Verastem Oncology: New RAMP 201 Molecular
Profiling and External Control Arm Analyses
Describing Outcomes for Avutometinib Plus
Defactinib in Recurrent Low-Grade Serous
Ovarian Cancer to be Presented at IGCS 2026 More
- Zealand Pharma: Opening of New Research
Hub in Cambridge, Massachusetts
More
|
|
 |
 |
CRCFO
Advisory
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
- Akebia Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Candel Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4)
More
- Damora Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Karyopharm Therapeutics: Inducement Grant
Under Nasdaq Listing Rule 5635(c)(4) More
- LSN: Hot Investor Mandates (Updated 9/29) More
- NORD: Awards Seed Grants to Advance
Breakthroughs in Rare Disease Research More
- Solid Biosciences: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
|
|
 |
| The
future of advanced therapies:
Explore challenges and
opportunities shaping patient
access, site-of-care expansion and
commercialization. |
| Access the
Report → |
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Kate
Torchilin, Ph.D., M.B.A., CEO and President,
Mirai Bio More
- BioPharmGuy News: Tasty & Terrible Name,
Suddenly Sober, All Boxes Ticked, A Bananas
Choice More
- Biotech & Pharma Updates | October 1,
2026 More
- Broad Institute: Catalog of Mitochondria
Across Life’s Family Tree Unearths New Roles
for the Cell’s Powerhouse More
- David Sinclair’s Latest Salvo Aims to Stall
Aging With a Pill More*
- More on Monte Rosa Therapeutics
Investigational Drug Showing Potential for
Cardiovascular Disease More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- VENT-03 (Iptocigistat): A Potential Oral
Therapy for Lupus and Other Type 1
Interferonopathies More*
|
|
 |
 |
| Slone
Partners Places Farhad Ghavami as
Chief Executive Officer at
SeqCenter |
|
Learn More
→ |
|
|
- Biopharma Recruiters See ‘Signs of Recovery’
as Layoffs Remain Cool in Q3’26 More
- More on Foghorn Laying Off 40% of
Employees as Lilly Cancer Collab Collapses
Over Poor Data More
More
More*
More*
- OPPORTUNITY: Vice President, Business
Development, Remote More
- OPPORTUNITY: Director of Compliance, Remote
More
- Slone Partners: Beyond the Org Chart
- Redefining Leadership Roles After an
Acquisition More
- Talawar Therapeutics: Appoints Industry
Veterans Mittie Doyle, MD, and Susannah Gray
to Board of Directors More
|
|
 |
Events
|
Note:
Events may be in any Big4Bio region or
virtual |
|
- Biocom’s San Diego Life Science CEO
Summit Oct
8
- MassBioEd’s 25th Anniversary Gala Oct
21
- Biocom’s Bay Area CEO Summit Oct
23
- Biocom’s Greater LA CEO Summit Oct
27
- BioFuture Oct
27-28
- PODD: Partnership Opportunities in
Drug Delivery Oct
29-30
- Scaling Academic Research Programs
Through Strategic Colony Management
Partnerships Nov
11
- 23rd Annual Pantheon Awards
Nov 12
- 2026 LSPA Patient Summit Nov
12
- Patient Pathways (Use code 26B4B10
for 10% off) Nov
17-20
|
SEE FULL
EVENT SCHEDULE AT THE BIOCALENDAR
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
